Market Research Report
Global Elastography Imaging Market, Size, Share, Opportunities and Forecast, 2020-2027
|Published by||DataM Intelligence||Product code||879281|
|Published||Content info||180 Pages
Delivery time: 2 business days
|Global Elastography Imaging Market, Size, Share, Opportunities and Forecast, 2020-2027|
|Published: April 3, 2021||Content info: 180 Pages||
Global Elastography Imaging Market is segmented by Modality (Ultrasound, Magnetic Resonance Elastography), by Application (Radiology, Cardiology, OB/GYN, Vascular, Orthopedic and Musculoskeletal), by End-User (Hospital, Surgery Center, Diagnostic Center), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020-2027
The Global Elastography Imaging Market is expected to grow at a CAGR of 7.80% during the forecasting period (2020-2027).
Elastography is a method of imaging that produces a type of image, called an elastogram. This diagnostic, noninvasive technique is used to map the elastic properties and stiffness of soft tissues, which gives information about the presence or status of the disease. For example, diseased livers are stiffer than healthy ones, and cancerous tumors often appear harder than the surrounding tissue. Elastography is used for the investigation of many disease conditions in many organs. It can be used for additional diagnostic information compared to an anatomical image, and it can be used to guide biopsies or replace them entirely.
The global market for the Elastography Imaging Market is primarily driven by the increasing occurrence of chronic liver diseases and breast cancer and a growing preference for minimally invasive procedures across the world. For instance, a meta-analysis study (Younossi 2017), concluded that the worldwide prevalence of Nonalcoholic fatty liver disease (NAFLD) was estimated at 25.2%. Alcohol is the chief cause of liver-related death in Europe with the highest mortality rates reported in Spain and France of approximately 30 deaths per 100,000 annually. According to the World Health Organization (WHO), alcohol consumption accounts for 3.8% of the global mortality and 4.6% of DALYs of which liver disease represents 9.5% of alcohol-related DALY. According to the American Institute of Cancer Research (AICR), breast cancer is the most commonly occurring cancer in women, and there were over 2 million new cases in 2018. The rising awareness regarding breast cancer and favorable government initiatives in the US and Europe by the government, along with increased government expenditure over healthcare facilities are expected to aid the market positively.
Other factors propelling the market are technological innovations by key market players to address the challenges seen in the current imaging technologies. For instance, according to the WHO, 1.9 billion people globally are reported as overweight, with 650 million people classified as obese. Ultrasound imaging relies on echo signals to produce images, and patients with more adipose tissue are more difficult to image. The deeper an echo signal needs to penetrate, the more the image quality is degraded. In attempting to overcome this, in July 2018, Siemens Healthineers launched a new ultrasound system called Acuson Sequoia. Its features enable high-resolution imaging that adapts to patients' size and personal characteristics, contributing to a more confident diagnosis. The new Deep Abdominal Transduce, elastography, and contrast-enhanced ultrasound allow the Acuson Sequoia to penetration up to 40cm.
However, the unfavorable reimbursement scenario and the high cost of elastography imaging systems may hinder market progress.
By Type, the Global Elastography Imaging Market is bifurcated into Ultrasound and Magnetic Resonance Elastography. The ultrasound segment holds the most significant market share owing to it being the most commonly performed technique and its advantages, such as its relatively low cost, quicker procedures, and broader availability and modality. Moreover, the recent product launches, such as ARIETTA 65, are expected to propel the market further. However, ultrasound elastography imaging can be unreliable in obese patients, and Magnetic Resonance elastography imaging offers a higher diagnostic accuracy, which is driving the MR market.
By Application, the Global Elastography Imaging Market is segmented into Radiology, Cardiology, Obstetrics, Urology, Vascular, Orthopedic & Musculoskeletal, and Others. The radiology sector holds the largest market share due to the extensive use of ultrasound in image-guided radiotherapy and radiology ultrasound (non-radiation-based procedures). Additionally, the easy availability of elastography systems, a growing number of skilled radiologists coupled with the ever increasing incidences of various cancers are expected to boost the market share further. Cardiology is anticipated to be a fast growing domain due to rising rates of cardiovascular disorders.
North America accounts for the largest share in the global Elastography Imaging market. This can be mainly attributed to factors such as rising incidents of cancer and chronic liver diseases in the region, the increasing awareness and growing adoption of advanced imaging techniques and early commercialization of devices in the region. For instance, according to the Canadian Cancer Society, 2016, an estimated 130.1 cases per 100,000 women were diagnosed with breast cancer in Canada. According to the American Cancer Society, more than 3.5 million US women with a history of breast cancer were alive on January 1, 2016. This includes women currently being treated and women who have finished treatment. According to the Centers for Disease Control and Prevention, in 2017, 4.5 million adults were diagnosed with liver disease in the US. Moreover, the advanced regional healthcare infrastructure, rise in healthcare expenditure, the presence of established market players, and high investment in R&D activities by them are likely to boost the North America Elastography Imaging market growth. Other factors such as growing government initiatives in for cancer screening that includes ultrasound systems featuring elastography has further increased the regional market growth.
The Asia Pacific is expected to show substantial market growth due to the increasing prevalence of breast cancer in the region. For instance, according to the International Association of Cancer Registries, Asia accounts for 39% of all breast cancers cases diagnosed globally. Other factors such as the rising adoption of ultrasound systems featuring elastography imaging along with the growing presence of significant players region are expected to enhance the regional market's development further.
To increase user base and improve their Elastography Imaging market presence, companies are increasingly launching innovative products, growing FDA approvals, and have substantial R&D investments. Several companies have adopted merger and acquisitions policies, geographic expansion, and collaborations to help them to stand out as strong competitors in the market and also expand its sales in the global Elastography Imaging market.
Major Players in the global Elastography Imaging market include SuperSonic, Siemens Healthineers, Philips Healthcare, Samsung Medison, and Hitachi.
In May 2019, JW Medical, a subsidiary of JW Holdings, announced that it has begun to market ARIETTA 65, an ultrasonic imaging device made by Hitachi Medical Systems. The ARIETTA 65 is an upgraded version of Hitachi's Aloka Arietta 850, which the company launched in February of last year. A vital characteristic of the device includes its battery mode, and can scan up to 60 minutes, which is the longest time for any commercially available ultrasound imaging devices to operate without a power source. ARIETTA 65 also employed the world's first strain elastography function, which allows automatic frame selection and calculates the elasticity of the lesion compared to the adipose tissue, thereby reducing the test time by 65% compared to conventional products.
In October 2018, Philips debuted an integrated breast ultrasound solution, available with the Philips Epiq and Affiniti ultrasound systems, and the combination of the eL18-4 transducer and anatomical intelligence. It is the first dedicated Philips ultrasound solution for breast assessment, combining advanced imaging, full solution elastography, screening, and precision biopsy. With the new breast solution, clinicians can efficiently assess, monitor, and treat breast diseases, increasing diagnostic confidence, and helping to improve patient care. The Philips ultrasound solution for breast assessment is CE marked and has received 510(k) clearance from the US Food and Drug Administration (FDA).
In July 2018, SuperSonic Imagine, a company specialized in ultrasound medical imaging, announces it has received 510(k) clearance from the US Food and Drug Administration (FDA) and authorization to use the CE marking from the LNE/GMed for its new cutting-edge smart ultrasound system, the Aixplorer MACH 30. The Aixplorer MACH 30 ultrasound system applies an advanced ShearWave elastography solution dubbed ShearWave PLUS. This technology offers users real-time, reliable, quantitative, and reproducible 2D and 3D visualization and evaluation of tissue stiffness. Shortening acquisition speed and increasing examination depth for more reliable diagnostic data, this new generation of elastography technology highlights the superior capabilities developed by SuperSonic Imagine.
Aerial Imaging Market
Breast Imaging Market